دورية أكاديمية
أعرض في EDS

A Review of Major Patents on Potential Malaria Vaccine Targets.

التفاصيل البيبلوغرافية
العنوان: A Review of Major Patents on Potential Malaria Vaccine Targets.
المؤلفون: Mariano RMDS; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Gonçalves AAM; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Oliveira DS; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Ribeiro HS; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Pereira DFS; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Santos IS; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Lair DF; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Silva AVD; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Galdino AS; Laboratory of Biotechnology of Microorganisms, Federal University of São João Del-Rei, Divinópolis CEP 35501-296, MG, Brazil., Chávez-Fumagalli MA; Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José S/N, Arequipa 04000, Peru., Silveira-Lemos DD; Campus Jaraguá, University José of Rosário Vellano, UNIFENAS, Belo Horizonte CEP 31270-901, MG, Brazil., Dutra WO; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil., Giunchetti RC; Laboratory of Biology of Cell Interactions, Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte CEP 31270-901, MG, Brazil.
المصدر: Pathogens (Basel, Switzerland) [Pathogens] 2023 Feb 03; Vol. 12 (2). Date of Electronic Publication: 2023 Feb 03.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101596317 Publication Model: Electronic Cited Medium: Print ISSN: 2076-0817 (Print) Linking ISSN: 20760817 NLM ISO Abbreviation: Pathogens Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, 2012-
مستخلص: Malaria is a parasitic infection that is a great public health concern and is responsible for high mortality rates worldwide. Different strategies have been employed to improve disease control, demonstrating the ineffectiveness of controlling vectors, and parasite resistance to antimalarial drugs requires the development of an effective preventive vaccine. There are countless challenges to the development of such a vaccine directly related to the parasite's complex life cycle. After more than four decades of basic research and clinical trials, the World Health Organization (WHO) has recommended the pre-erythrocytic Plasmodium falciparum (RTS, S) malaria vaccine for widespread use among children living in malaria-endemic areas. However, there is a consensus that major improvements are needed to develop a vaccine with a greater epidemiological impact in endemic areas. This review discusses novel strategies for malaria vaccine design taking the target stages within the parasite cycle into account. The design of the multi-component vaccine shows considerable potential, especially as it involves transmission-blocking vaccines (TBVs) that eliminate the parasite's replication towards sporozoite stage parasites during a blood meal of female anopheline mosquitoes. Significant improvements have been made but additional efforts to achieve an efficient vaccine are required to improve control measures. Different strategies have been employed, thus demonstrating the ineffectiveness in controlling vectors, and parasite resistance to antimalarial drugs requires the development of a preventive vaccine. Despite having a vaccine in an advanced stage of development, such as the RTS, S malaria vaccine, the search for an effective vaccine against malaria is far from over. This review discusses novel strategies for malaria vaccine design taking into account the target stages within the parasite's life cycle.
References: Expert Rev Vaccines. 2015 May;14(5):653-80. (PMID: 25597923)
Int J Antimicrob Agents. 2020 Mar;55(3):105924. (PMID: 32081636)
J Infect Dis. 2007 Aug 15;196(4):608-16. (PMID: 17624848)
Expert Rev Vaccines. 2012 Oct;11(10):1261-80. (PMID: 23176657)
J Immunol Res. 2018 Mar 25;2018:6529681. (PMID: 29765991)
Front Immunol. 2018 Nov 29;9:2769. (PMID: 30555463)
Malar J. 2011 Jul 14;10:192. (PMID: 21756349)
Lancet. 2001 Dec 8;358(9297):1927-34. (PMID: 11747915)
Nat Commun. 2018 Jul 12;9(1):2686. (PMID: 30002445)
Lancet Infect Dis. 2022 Dec;22(12):1728-1736. (PMID: 36087586)
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2806-14. (PMID: 21893544)
J Infect Dis. 2016 Sep 1;214(5):762-71. (PMID: 27296848)
Pediatr Res. 2021 Apr;89(5):1078-1086. (PMID: 32971527)
Am J Trop Med Hyg. 1992 Apr;46(4):391-7. (PMID: 1374220)
Expert Opin Emerg Drugs. 2005 Aug;10(3):489-503. (PMID: 16083325)
NPJ Vaccines. 2020 Jun 9;5(1):48. (PMID: 32566259)
J Mark Access Health Policy. 2017 Aug 31;5(1):1336044. (PMID: 29785253)
Med Clin (Barc). 2020 Nov 13;155(9):395-402. (PMID: 32620355)
Nat Med. 2004 Apr;10(4):406-10. (PMID: 15034567)
N Engl J Med. 2009 Jul 30;361(5):468-77. (PMID: 19641203)
Vaccine. 2012 Mar 30;30(16):2662-70. (PMID: 22342550)
Infect Immun. 2001 Mar;69(3):1536-46. (PMID: 11179324)
PLoS One. 2016 Oct 17;11(10):e0163144. (PMID: 27749907)
BMC Med. 2019 Aug 14;17(1):157. (PMID: 31409398)
Semin Immunol. 2013 Apr;25(2):146-51. (PMID: 23757291)
Lancet Infect Dis. 2018 Sep;18(9):969-982. (PMID: 30061051)
Lancet Glob Health. 2020 Sep;8(9):e1102-e1103. (PMID: 32673576)
Trends Parasitol. 2001 May;17(5):236-42. (PMID: 11323308)
Future Microbiol. 2018 May;13:609-612. (PMID: 29624074)
Cell Host Microbe. 2020 Oct 7;28(4):504-506. (PMID: 33031767)
Infect Immun. 2008 Apr;76(4):1702-8. (PMID: 18268027)
Science. 2011 Oct 28;334(6055):475-80. (PMID: 21903775)
J Infect Dis. 2020 Oct 13;222(10):1681-1691. (PMID: 32687161)
Trends Parasitol. 2019 Jul;35(7):483-486. (PMID: 31153722)
Vaccine. 2021 Jan 22;39(4):687-698. (PMID: 33358704)
Eur J Immunol. 1997 Oct;27(10):2502-13. (PMID: 9368603)
Cell Host Microbe. 2013 Jan 16;13(1):29-41. (PMID: 23332154)
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):998-1002. (PMID: 28096331)
J Clin Invest. 2010 Dec;120(12):4168-78. (PMID: 21123952)
Clin Infect Dis. 2008 Aug 1;47(3):401-9. (PMID: 18558875)
Braz J Med Biol Res. 2013 Feb;46(2):109-16. (PMID: 23369975)
Hum Vaccin. 2010 Jan;6(1):97-106. (PMID: 19946222)
Parasitology. 2007 Dec;134(Pt.14):1911-29. (PMID: 17714601)
Nature. 2002 Oct 3;419(6906):498-511. (PMID: 12368864)
Mem Inst Oswaldo Cruz. 2010 Feb;105(1):1-12. (PMID: 20209323)
Lancet. 2007 Nov 3;370(9598):1543-51. (PMID: 17949807)
Genomics. 2012 Feb;99(2):69-75. (PMID: 22178265)
Mol Microbiol. 2006 Aug;61(4):991-8. (PMID: 16879650)
Parasitol Int. 2021 Feb;80:102224. (PMID: 33137499)
Parasite Immunol. 2021 Feb;43(2):e12795. (PMID: 32981095)
Trends Parasitol. 2007 Mar;23(3):122-8. (PMID: 17258937)
Cell Host Microbe. 2008 Sep 11;4(3):209-18. (PMID: 18779047)
PLoS One. 2016 Dec 2;11(12):e0166814. (PMID: 27911910)
PLoS Pathog. 2011 Sep;7(9):e1002199. (PMID: 21909261)
Recent Pat Biotechnol. 2019;13(3):170-186. (PMID: 30648529)
Nat Nanotechnol. 2021 Jan;16(1):16-24. (PMID: 33199883)
Exp Parasitol. 2001 Jan;97(1):45-9. (PMID: 11207113)
Indian J Malariol. 1954 Dec;8(4):257-62. (PMID: 14391879)
Lancet. 2019 Apr 27;393(10182):1685. (PMID: 31034365)
Nat Mater. 2019 Feb;18(2):175-185. (PMID: 30643235)
Cold Spring Harb Perspect Med. 2017 Mar 1;7(3):. (PMID: 27836912)
J Infect Dis. 2008 Feb 15;197(4):519-26. (PMID: 18275273)
Eukaryot Cell. 2007 Aug;6(8):1260-5. (PMID: 17557884)
PLoS Pathog. 2015 Jun 18;11(6):e1004871. (PMID: 26086192)
N Engl J Med. 2016 Jun 30;374(26):2519-29. (PMID: 27355532)
Cell. 2001 Jan 12;104(1):153-64. (PMID: 11163248)
Vaccine. 2001 Mar 21;19(17-19):2309-14. (PMID: 11257353)
Cell Host Microbe. 2020 Oct 7;28(4):572-585.e7. (PMID: 32697938)
Elife. 2017 Feb 22;6:. (PMID: 28226242)
PLoS One. 2012;7(2):e31247. (PMID: 22355349)
Chem Immunol. 2002;80:188-203. (PMID: 12058639)
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9286-91. (PMID: 16751273)
PLoS One. 2013 Apr 16;8(4):e61395. (PMID: 23613845)
Vaccine. 2007 Jan 15;25(5):886-94. (PMID: 17049690)
فهرسة مساهمة: Keywords: malaria vaccine; patents; stage of development
تواريخ الأحداث: Date Created: 20230225 Latest Revision: 20230228
رمز التحديث: 20230228
مُعرف محوري في PubMed: PMC9959516
DOI: 10.3390/pathogens12020247
PMID: 36839519
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-0817
DOI:10.3390/pathogens12020247